ArticlePloS one2026
GraphTransDTI: A novel hybrid framework combining graph transformer and CNN-BiLSTM for enhanced Drug-Protein Interaction prediction.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-protein interaction (DTI) prediction is a pivotal step in the drug discovery and repurposing process, helping to minimize experimental costs and time. However, existing deep learning methods often face limitations in simultaneously capturing the spatial structure of drug molecules and the deep contextual correlation with protein sequences. To address this issue, we propose GraphTransDTI, a synergistic hybrid framework that integrates a Graph Transformer to represent drug graph structures, a CNN-BiLSTM network to encode protein sequence context, and a Cross-Attention mechanism to model cross-domain interactions. Comprehensive experiments on two benchmark datasets, KIBA and Davis, across three rigorous scenarios: random splits, cold drug splits, and cold target splits demonstrate that GraphTransDTI achieves competitive performance compared to current state-of-the-art baseline models. Our findings confirm that the strategic combination of graph structural information and sequential attention mechanisms significantly enhances prediction accuracy and robustness in cold-start scenarios, offering a reliable and well-validated approach for high-precision virtual drug screening systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.